St. Jude People

Jessica Gartrell, MD

Assistant Member, St. Jude Faculty

Explore Jessica Gartrell's research

On this page:

Contact Information

Jessica Gartrell, MD

Solid Tumor

MS 260, Room C6006

St. Jude Children's Research Hospital

262 Danny Thomas Place

Memphis,  TN 38105-3678

(901) 595-3509(phone)

Affiliations

Department of Oncology

Solid Tumor Division

Comprehensive Cancer Center

Developmental Biology and Solid Tumor Program

Education

BS (Psychology) - University of Nebraska, Lincoln, Lincoln, NE MD – University of Nebraska Medical Center, Omaha, NE Residency (Pediatrics) – University of Tennessee Health Science Center, Memphis, TN Fellowship (Pediatric Hematology/Oncology) – St. Jude Children’s Research Hospital, Memphis, TN Fellowship (Pediatric Solid Tumor) – St. Jude Children’s Research Hospital, Memphis, TN Graduate Certificate (Clinical & Translational Research) – University of Cincinnati, Cincinnati, OH

Research Interests

  • Developing early phase clinical trials that lead to the identification of therapeutic biomarkers and novel combination therapies for high risk sarcomas and liver tumors

Clinical Trials

Recruiting
ANGIO-A: Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumors

Study goal:

In Part 1 of this study, we will see if sorafenib, cyclophosphamide, bevacizumab, and atezolizumab can be given safely together without causing serious side effects. Part 2 of the study will find out how well these medicines work in hepatocellular carcinoma, fibrolamellar carcinoma, desmoplastic small round cell tumors, and malignant rhabdoid tumors.

Age:

1-30 years old

Recruiting
NRSTS2021: A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy, and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma

Study goal:

The purpose of this clinical trial is to find better treatments for NRSTS patients who are intermediate- and high-risk. Our goal is to lower the risk of the tumor coming back after treatment, while using treatments with fewer risks of long-term side effects.

Age:

Up to 30 years old.

Recruiting
PEPN2011: Tegavivint Treatment for Solid Tumors, Lymphomas, and Desmoid Tumors

Study goal:

The main purpose of this study is to find out how well the medicine tegavivint works to help children, teens, and young adults with certain recurrent or refractory solid tumors.

Age:

12 months to 30 years

Recruiting
PEPN2111: Phase 1/2 Trial of CBL0137 for Relapsed or Refractory Solid Tumors and Lymphoma

Study goal:

The main purpose of this study is to find the highest, safest dose of CBL0137 that can be given to children, teens and young adults with solid tumors or lymphoma.

Age:

12 months to 21 years old with diagnosis of relapsed or refractory solid tumor or lymphoma (including CNS tumors) or progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy; 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma

St. Jude Publications